University of Illinois Chicago
Browse

Obestatin Plays an Opposite Role in the Regulation of Pituitary Somatotrope and Corticotrope Function in Female Primates and Male/Female Mice

Download (256.02 kB)
journal contribution
posted on 2017-01-14, 00:00 authored by R.M. Luque, J. Córdoba-Chacón, I. Gesmundo
Obestatin is a 23-amino-acid amidated peptide that is encoded by the ghrelin gene. Previous studies have shown obestatin can modulate the hypothalamic neuronal circuitry that regulates pituitary function, perhaps by modulating the actions of ghrelin. However, the direct actions of obestatin on pituitary function remain controversial. Here, primary pituitary cell cultures from a nonhuman primate (baboon) and mice were used to test the effects of obestatin on pituitary hormone expression and secretion. In pituitary cultures from both species, obestatin had no effect on prolactin, LH, FSH, or TSH expression/release. Conversely, obestatin stimulated proopiomelanocortin expression and ACTH release and inhibited GH expression/release in vitro, actions that were also observed in vivo in mice treated with obestatin. In vitro, obestatin inhibited the stimulatory actions of ghrelin on GH but not ACTH release. The inhibitory effect of obestatin on somatotrope function was associated with an overall reduction in pituitary transcription factor-1 and GHRH receptor mRNA levels in vitro and in vivo as well as a reduction in hypothalamic GHRH and ghrelin expression in vivo. The stimulatory effect of obestatin on ACTH was associated with an increase in pituitary CRF receptors. Obestatin also reduced the expression of pituitary somatostatin receptors (sst1/sst2), which could serve to modify its impact on hormone secretion. The in vitro actions of obestatin on both GH and ACTH release required the adenylyl cyclase and MAPK routes. Taken together, our results provide evidence that obestatin can act directly at the pituitary to control somatotrope and corticotrope function, and these effects are conserved across species

Funding

This work was supported by the following grants: Junta de Andalucía (BIO-0139, CTS-5051, CTS-1406, PI-0369 –2012), Ministerio de Economía y Competitividad, Gobierno de España (BFU2010 –19300), Instituto de Salud Carlos III (PI13/00651, and “Sara Borell Program” CD11/00276), Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBERobn) and Ayuda Merck Serono 2013 (to R.M.L, A.I.-C., M.D.G., and J.P.C) and BFI2011-25021 (to M.T.-S.); Compagnia di San Paolo 2011 and Ministero dell’Istruzione, dell’Università e della Ricerca 2009 (to R.G.); Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Merit Award and the National Institutes of Health Grants R21AG031465 and R01DK088133 (to R.D.K.). Ciber is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain.

History

Publisher Statement

This is a copy of an article published in Endocrinology © 2014 Endocrine Society Publications. endo.endojournals.org

Publisher

Endocrine Society

issn

: 0013-7227

Issue date

2014-04-01

Usage metrics

    Categories

    No categories selected

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC